Estimated read time: Less than a minute
This archived news story is available only for your personal, non-commercial use. Information in the story may be outdated or superseded by additional information. Reading or replaying the story in its archived form does not constitute a republication of the story.
Alexion Pharmaceuticals is spending about $8.4 billion - a huge premium — to buy Synageva BioPharma, a fellow rare disease treatment developer with no products on the market that booked a first-quarter loss of nearly $60 million.
Alexion will pay $115 in cash and a portion of its stock for each Synageva share. That puts the total per-share price at about $226, based on Alexion's Tuesday closing price.
That's more than double the value Synageva BioPharma Corp.'s closing price of $95.87 on Tuesday. Shares of the drugmaker are soaring in premarket trading.
Alexion Pharmaceuticals Inc. is based in Cheshire, Connecticut, and makes Soliris, which is approved to treat a rare, life-threatening blood disorder called paroxysmal nocturnal hemoglobinuria.
Synageva's lead product in development, the rare disease treatment Kanuma, is being reviewed by federal regulators.
Copyright © The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.